[{"address1": "55 Flemington Road", "address2": "Suite 401", "city": "North Melbourne", "state": "VIC", "zip": "3051", "country": "Australia", "phone": "61 3 9093 3855", "website": "https://telixpharma.com", "industry": "Biotechnology", "sector": "Healthcare", "longBusinessSummary": "Telix Pharmaceuticals Limited, a commercial-stage biopharmaceutical company, focuses on the development and commercialization of therapeutic and diagnostic radiopharmaceuticals for cancer and rare diseases in Australia, Belgium, Japan, Switzerland, and the United States. The company offers Illuccix for the treatment of prostate cancer; and TLX66-CDx for the treatment of imaging osteomyelitis. Its products candidates include TLX591, a radio antibody-drug conjugate for the treatment of prostate cancer; TLX250-CDx for the treatment and diagnosis of renal (kidney) cancer; TLX101-CDx for brain (glioma) cancer; TLX66-CDx to treat bone marrow conditioning; TLX300-CDx for the treatment and diagnosis of soft tissue sarcoma; and TLX250 for the treatment of clear cell renal cell carcinoma. The company also develops TLX101 for the treatment of glioblastoma (brain cancer); TLX66 for the treatment of bone marrow conditioning; TLX300 for the treatment of soft tissue sarcoma; and TLX592, a prostate cancer therapy candidate for targeted alpha therapy. Telix Pharmaceuticals Limited was founded in 2015 and is headquartered in North Melbourne, Australia.", "companyOfficers": [{"maxAge": 1, "name": "Dr. Christian P. Behrenbruch BEng(Hons), DPhil(Oxon), GAICD, J.D., M.B.A., MBA", "age": 47, "title": "Co-Founder, MD, Group CEO & Executive Director", "yearBorn": 1976, "fiscalYear": 2023, "totalPay": 454246, "exercisedValue": 0, "unexercisedValue": 1455264}, {"maxAge": 1, "name": "Mr. Darren  Smith B.Bus., FCPA, M.B.A.", "age": 58, "title": "Group Chief Financial Officer", "yearBorn": 1965, "fiscalYear": 2023, "totalPay": 387685, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Andreas  Kluge M.D., Ph.D.", "age": 58, "title": "Chief Medical Advisor & Non-Executive Director", "yearBorn": 1965, "fiscalYear": 2023, "totalPay": 29186, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. David N. Cade M.B.A., M.D., MBBS", "age": 54, "title": "Group Chief Medical Officer", "yearBorn": 1969, "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Darren  Patti", "age": 51, "title": "Group Chief Operating Officer", "yearBorn": 1972, "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Michael  Wheatcroft B.Sc., BSc(Hons), Ph.D., Ph.D., (Cantab)", "title": "Chief Scientist", "fiscalYear": 2023, "totalPay": 96223, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Craig  Ulrick", "title": "Chief Information Officer", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Ms. Kyahn  Williamson B.A.", "title": "Senior Vice President of Corporate Communications & Investor Relations", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Ms. Melanie  Farris (AGIA, ACG, ACIS) BComn, B.Com., GradDip, M.A.I.C.", "title": "Senior Vice President of Global Governance, Risk & Compliance", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Ms. Lena  Moran-Adams L.L.B.", "title": "Group General Counsel", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}], "auditRisk": 3, "boardRisk": 6, "compensationRisk": 5, "shareHolderRightsRisk": 7, "overallRisk": 6, "governanceEpochDate": 1725148800, "compensationAsOfEpochDate": 1703980800, "maxAge": 86400, "priceHint": 2, "previousClose": 12.0, "open": 12.0, "dayLow": 11.89, "dayHigh": 12.15, "regularMarketPreviousClose": 12.0, "regularMarketOpen": 12.0, "regularMarketDayLow": 11.89, "regularMarketDayHigh": 12.15, "beta": 2.401, "trailingPE": 117.0, "volume": 4050, "regularMarketVolume": 4050, "averageVolume": 10867, "averageVolume10days": 3615, "averageDailyVolume10Day": 3615, "bid": 11.7, "ask": 11.99, "bidSize": 40000, "askSize": 40000, "marketCap": 3915288064, "fiftyTwoWeekLow": 5.3, "fiftyTwoWeekHigh": 14.59, "priceToSalesTrailing12Months": 6.0638494, "fiftyDayAverage": 12.684002, "twoHundredDayAverage": 9.589206, "currency": "USD", "enterpriseValue": 3813813248, "profitMargins": 0.07618, "floatShares": 262729275, "sharesOutstanding": 334640000, "heldPercentInsiders": 0.25854, "heldPercentInstitutions": 0.17527, "bookValue": 1.209, "priceToBook": 9.67742, "lastFiscalYearEnd": 1703980800, "nextFiscalYearEnd": 1735603200, "mostRecentQuarter": 1719705600, "netIncomeToCommon": 49185000, "trailingEps": 0.1, "enterpriseToRevenue": 5.907, "enterpriseToEbitda": 52.143, "exchange": "PNK", "quoteType": "EQUITY", "symbol": "TLPPF", "underlyingSymbol": "TLPPF", "shortName": "Telix Pharmaceutical Ltd.", "longName": "Telix Pharmaceuticals Limited", "firstTradeDateEpochUtc": 1564061400, "timeZoneFullName": "America/New_York", "timeZoneShortName": "EDT", "uuid": "fcf3fddf-22fc-3e4e-843b-3462ea6ddebf", "gmtOffSetMilliseconds": -14400000, "currentPrice": 11.7, "recommendationKey": "none", "totalCash": 118837000, "totalCashPerShare": 0.356, "ebitda": 73142000, "totalDebt": 22143000, "quickRatio": 0.806, "currentRatio": 0.988, "totalRevenue": 645676992, "debtToEquity": 5.481, "revenuePerShare": 1.991, "returnOnAssets": 0.0797, "returnOnEquity": 0.20492001, "freeCashflow": 105929752, "operatingCashflow": 49706000, "revenueGrowth": 0.581, "grossMargins": 0.62779, "ebitdaMargins": 0.11328, "operatingMargins": 0.09494001, "financialCurrency": "AUD", "trailingPegRatio": null, "__fetch_time": "2024-09-05"}]